%0 Journal Article
%T PCSK9抑制剂在脂质代谢和动脉粥样硬化中的应用<br>Application of PCSK9 Inhibitors in Lipid Metabolism and Arteriosclerosis
%A 刘扬
%A 罗健
%J Advances in Clinical Medicine
%P 12430-12438
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.1381742
%X 自2003年在家族性高胆固醇血症中发现致病基因前蛋白转化酶枯草杆菌素9 (PCSK9)以来，以PCSK9为靶点的研究进展迅速。近年来PCSK9抑制剂被证实具有良好的降低血脂作用，还有潜在的抗炎、降低心血管风险作用，已经作为一种新型降脂药物应用于心血管疾病。现对PCSK9基因与脂质代谢的关系、PCSK9抑制剂的临床研究进展和PCSK9抑制剂的安全性等进行综述。<br />
Since the discovery of the pathogenic gene proprotein convertase subtilisin 9 (PCSK9) in familial hypercholesterolemia in 2003, studies of targeting PCSK9 have progressed rapidly. In recent years, PCSK9 inhibitors have been proven to have good lipid-lowering effects, as well as potential an-ti-inflammatory and cardiovascular risk-reducing effects, and have been used as a new type of li-pid-lowering drugs in cardiovascular diseases. This article reviews the relationship between PCSK9 gene and lipid metabolism, the clinical research progress of PCSK9 inhibitors and the safety of PCSK9 inhibitors.
%K PCSK9抑制剂，低密度脂蛋白胆固醇(LDL-C)，动脉粥样硬化，炎症<br>PCSK9 Inhibitors
%K Low-Density Lipoprotein Cholesterol (LDL-C)
%K Arteriosclerosis
%K Inflammation
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=70360